Healthcare >> Analyst Interviews >> November 15, 2010
Michael Yee brings more than nine years of experience to RBC Capital Markets' biotechnology research team in San Francisco. Most recently, he was named "Best Up and Comer" in the biotechnology sector in Institutional Investor's 2010 All-America Research Team. Mr. Yee joined RBC Capital Markets in 2005, after working at WR Hambrecht & Co, where he covered biotechnology. Mr. Yee also worked at Deutsche Bank Securities Inc. and Thomas Weisel Partners LLC, where he worked in life science tools equity research from 2001 to 2004 . Mr. Yee earned a B.A. in molecular cell biology from the University of California, Berkeley, and an MBA from the University of California, Berkeley, Haas School of Business. Profile
TWST: You are the Director of Equity Research for RBC. What is your coverage?
Mr. Yee: I cover small-, mid- and large-cap therapeutic biotechnology, which are the drug companies. I cover Acorda
